


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the unaudited financial information currently available, profit attributable to shareholders of the Company for the six months ended 30 June 2023 (“**1H2023**”) is expected to be in the range of HK\$25.0 million to HK\$30.0 million, or an increase of around 68% to 102%, as compared with profits of HK\$14.8 million for the same period last year.

The expected increase in profit attributable to shareholders of the Company was primarily driven by an over 40% increase in revenue generated from medical service to approximately HK\$930.0 million in 1H2023 from HK\$660.8 million for the same period last year, partially net off by the reduction in revenue generated from sale of COVID-19 related medical consumables to approximately HK\$19.0 million in 1H2023 from HK\$220.7 million for the same period last year. The significant increase in revenue generated from medical service is due to the strong post COVID-19 rebound in demand for both ophthalmic and dental service in both Hong Kong and Mainland China, and the reopening of the border between Hong Kong and Shenzhen. The total revenue of the Company is expected to increase to over HK\$950.0 million in 1H2023 from HK\$881.6 million for the same period last year.

As the Company is still in the process of finalising the results for 1H2023, the information contained in this announcement is based on the management's preliminary review on the management accounts of the Group and current information available to the Board and has not been reviewed and confirmed by the Company's auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for 1H2023, which is expected to be published by the end of August 2023.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu Dennis
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 17 August 2023

As of the date of this announcement, the Board comprises three executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting and Dr. LEE Yau Wing Vincent and four independent non-executive Directors, namely, Dr. Rex AU YEUNG Pak-kuen, Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen and Mr. YIN Ke.